Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ, ÀýÁ¦ ºÒ°¡´ÉÇÑ ÃéÀå¾Ï¿¡¼­ Á¤À§ ¹æ»ç¼± Ä¡·á Locally Advanced, Unresectable Pancreatic Cancer Treated by Stereotactic Radiation Therapy

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 1È£ p.11 ~ 20
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖö¿ø/Choi CW ±è¹Ì¼÷/Á¶Ã¶±¸/·ù¼º·Ä/¾ç±¤¸ð/À¯ÇüÁØ/À̵¿ÇÑ/Áö¿µÈÆ/ÇÑöÁÖ/±è Áø/±è¿µÇÑ/Kim MS/Cho CK/Yoo SY/Yang KM/Yoo HJ/Lee DH/Ji YH/Han CJ/Kim J/Kim YH

Abstract

¸ñ Àû: ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ, ÀýÁ¦ ºÒ°¡´ÉÇÑ ÃéÀå¾Ï Ä¡·á¿¡ ÀÖ¾î °í½ÄÀû ¹æ»ç¼± Ä¡·á¿Í ºñ±³ÇÏ¿© CyberKnife (CK)¸¦ ÀÌ¿ëÇÑ Á¤À§ ¹æ»ç¼± Ä¡·áÀÇ »ýÁ¸À² ¹× ±Þ¼º µ¶¼º¿¡ ´ëÇØ ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2003³â 4¿ùºÎÅÍ 2004³â 4¿ù±îÁöÀÇ, Eastern Cooperative Oncology Group (ECOG) È°µ¿µµ 3 ÀÌÇÏÀ̸ç CT ¹× PET/CT·Î Æò°¡ÇÏ¿© ¿ø°Ý ÀüÀÌ ¾ø´Â ±¹¼Ò ÁøÇàµÈ ÃéÀå¾Ï ȯÀÚ 19¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ´ë»ó ȯÀÚ´Â Á¡Â÷ ¹æ»ç¼±·®À» Áõ°¡½ÃÅ°´Â ¹æ¹ýÀ¸·Î 33 Gy, 36 Gy, 39 Gy¸¦ 3ºÐÇÒ·Î °¢°¢ 6¸í, 4¸í, 9¸í¿¡¼­ CK¸¦ ÀÌ¿ëÇÑ Á¤À§ ¹æ»ç¼± Ä¡·á¸¦ ½ÃÇàÇÏ¿´À¸¸ç, »ýÁ¸À² ¹× Radiation Therapeutic Oncology Group (RTOG) acute radiation morbidity criteria¿¡ ÀÇÇÑ À§Àå°ü µ¶¼ºÀ» ºÐ¼®ÇÏ¿´´Ù. ¶ÇÇÑ ³ªÀÌ, ¼ºº°, ECOG ¼öÇà Á¡¼ö, Ç×¾Ï Ä¡·á, ¿ìȸ·Î Á¶¼º¼ú(bypass surgery) ¿©ºÎ, ¹æ»ç¼±·®, CA19-9, °èȹ¿ë Ç¥Àû üÀû(planning target volume, PTV), CT»ó ÁÖÀ§ Àå±â ¹× Ç÷°ü ħ¹ü ¿©ºÎ µîÀ» Log Rank test¸¦ ÀÌ¿ëÇÏ¿© ¿¹ÈÄ ÀÎÀÚ¸¦ Æò°¡ÇÏ¿´´Ù.

°á °ú: º» ¿¬±¸¿¡¼­ Áß¾Ó »ýÁ¸ ±â°£Àº 11°³¿ù, 1³â »ýÁ¸À²Àº 36.8%¿´´Ù. ÃßÀû Á¶»ç ±â°£ Áß(¹üÀ§ 3¡­20°³¿ù, Áß¾Ó°ª 10°³¿ù) À¯ÀÇÇÑ À§Àå°ü ±Þ¼º µ¶¼ºÀº °üÂûµÇÁö ¾Ê¾Ò´Ù. ´ÜÀÏ ÀÎÀÚ ºÐ¼®¿¡¼­ °èȹ¿ë Ç¥Àû üÀû¸¸ÀÌ À¯ÀÇÇÑ ¿¹ÈÄ ÀÎÀÚ·Î 80 cc ÀÌÇÏÀÎ °æ¿ì°¡ 80 cc ÀÌ»óÀÎ °æ¿ìº¸´Ù »ýÁ¸À²ÀÌ ³ô¾ÒÀ¸¸ç(p-value£¼0.05), ³ªÀÌ, ¼ºº°, ECOG ¼öÇà Á¡¼ö, Ç×¾Ï Ä¡·á, ¿ìȸ·Î Á¶¼º¼ú, CA19-9 ¼öÄ¡, ÁÖÀ§ Àå±â ¹× Ç÷°ü ħ¹ü ¿©ºÎ µî¿¡¼­´Â Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù. ´ÙÀÎÀÚ ºÐ¼®¿¡¼­´Â 65¼¼ ÀÌÇÏÀÎ °æ¿ì¿Í PTV 80 cc ÀÌÇÏÀÎ °æ¿ì¿¡¼­ »ýÁ¸À²ÀÌ ³ô¾Ò´Ù.

°á ·Ð: °í½ÄÀû ¹æ»ç¼± Ä¡·á, °í¼±·® ÀÔüÁ¶Çü ¹æ»ç¼± Ä¡·á(high dose conformal radiation therapy), ¼ö¼ú Áß ¹æ»ç¼± Ä¡·á(intraoperative radiation therapy) ¶Ç´Â ¼¼±â Á¶Àý ¹æ»ç¼± Ä¡·á(intensity modulated radiation therapy, IMRT)¸¦ ÀÌ¿ëÇÑ ÃÖ±ÙÀÇ °á°ú¿Í ºñ±³ÇÏ¿© CK¸¦ ÀÌ¿ëÇÑ Á¤À§ ¹æ»ç¼± Ä¡·á´Â »ýÁ¸À² Ãø¸é¿¡¼­ ºñ½ÁÇϰųª ³ªÀº °á°ú¸¦ º¸¿´´Ù. ¶ÇÇÑ ½É°¢ÇÑ ºÎÀÛ¿ëÀº °üÂûµÇÁö ¾Ê¾ÒÀ¸¸ç ªÀº ±â°£ÀÇ Ä¡·á·Î ȯÀÚ¿¡°Ô ÆíÀǸ¦ Á¦°øÇÒ ¼ö ÀÖ¾î °á°úÀûÀ¸·Î »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖÀ» °ÍÀÌ´Ù. µû¶ó¼­, ÀÌ »õ·Î¿î Ä¡·á ¹æ¹ýÀº ±¹¼Ò ÁøÇàµÈ, ÀýÁ¦ ºÒ°¡´ÉÇÑ ÃéÀå¾Ï ȯÀÚ¿¡¼­ ½É°¢ÇÑ ºÎÀÛ¿ë ¾ø´Â È¿°úÀûÀÎ Ä¡·á°¡ µÉ °ÍÀ¸·Î »ý°¢µÈ´Ù. ¶ÇÇÑ °èȹ¿ë Ç¥Àû üÀûÀº CK Ä¡·áÀÇ À¯¿ëÇÑ ¿¹ÈÄ ÀÎÀÚ·Î »ç¿ëµÉ °ÍÀÌ´Ù.

Purpose: In order to find out whether stereotactic radiation therapy (RT) using CyberKnife (CK) could improve survival rate and lower acute toxicity compared to conventional RT.

Materials and Methods: From April 2003 through April 2004, 19 patients with Eastern Cooperative Oncology Group (ECOG) performance status ¡Â3 and locally advanced pancreas cancer without distant metastasis, evaluated by CT or PET/CT, were included. We administered stereotactic RT consisting of either 33 Gy, 36 Gy or 39 Gy in 3 fractions to 6, 4 and 9 patients, respectively, in an effort to increase the radiation dose step by step, and analyzed the survival rate and gastrointestinal toxicities by the acute radiation morbidity criteria of Radiation Therapeutic Oncology Group (RTOG). Prognostic factors of age, sex, ECOG performance score, chemotherapy, bypass surgery, radiation dose, CA19-9, planning target volume (PTV), and adjacent organ and vessel invasion on CT scan were evaluated by Log Rank test.

Results: The median survival time was 11 months with 1-year survival rate of 36.8%. During follow-up period (range 3¡­20 months, median 10 months), no significant gastrointestinal acute toxicity (RTOG grade 3) was observed. In univariate analysis, age, sex, ECOG performance score, chemotherapy, bypass surgery, radiation dose, CA19-9 level, and adjacent organ and vessel invasion did not show any significant changes of survival rate, however, patients with PTV (80 cc showed more favorable survival rate than those with PTV£¾80 cc (p-value£¼0.05). In multivariate analysis, age younger than 65 years and PTV£¾80 cc showed better survival rate.

Conclusion: In terms of survival, the efficacy of stereotactic radiation therapy using CK was found to be superior or similar to other recent studies achieved with conventional RT with intensive chemotherapy, high dose conformal RT, intraoperative RT (IORT), or intensity modulated RT (IMRT). Furthermore, severe toxicity was not observed. Short treatment time in relation to the short life expectancy gave patients more convenience and, finally, quality of life would be increased. Consequently, this could be regarded as an effective novel treatment modality for locally advanced, unresectable pancreas cancer. PTV would be a helpful prognostic factor for CK.

Å°¿öµå

ÃéÀå¾Ï;Á¤À§ ¹æ»ç¼± Ä¡·á;Pancreatic cancer;Stereotactic radiation therapy;CyberKnife

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS